Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China. (4th March 2014)

• Record Type: Journal Article
• Authors: Ma, J.; Liu, L. Y.; Wu, P. H.; Liao, Y.; Tao, T.; Liu, W.
• Other Names: Abderrahmani Amar Academic Editor.
• Is Part Of: Journal of diabetes research. Volume 2014(2014)
• Publication Date: 2014-03-04
• Subjects: Diabetes -- Periodicals; Diabetes -- Pathophysiology -- Periodicals; Diabetes -- Prevention -- Periodicals; Diabetes -- Etiology -- Periodicals; Diabetes -- Epidemiology -- Periodicals; Diabetes -- Pathogenesis -- Periodicals; 616.462005
• DOI: 10.1155/2014/294017
• Languages: English
• ISSNs: 2314-6745

Abstract

Abstract : Objective . This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China. Methods . A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated in the study. All patients received 3-month treatment of metformin or repaglinide. Fasting blood glucose and HbA1c were determined at baseline and at the end of the 3-month of treatment. Results . FPG and HbA1c decreased in both metformin and repaglinide groups after 3 months treatment ( P < 0.01 ) . The reduction of HbA1c was significantly greater in the repaglinide group ( P < 0.01 ) . Metformin decreases fasting insulin concentration and HOMA-IR ( P < 0.01 ), and repaglinide improves HOMA-β ( P < 0.01 ) . Triglycerides (TG) were reduced in both groups ( P < 0.01 in metformin group; P < 0.0 5 in repaglinide group), but total cholesterol (TC) and low-density lipoprotein (LDL) were decreased only after metformin treatment ( P < 0.0 5 ) . Conclusions . Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China. Repaglinide had no effect on insulin sensitivity, but it improved β -cell function.